Baker Bros. Advisors Reduces $21M in Roivant Sciences Ltd. ($ROIV)
Key Points
- Baker Bros. Advisors changed its Roivant Sciences Ltd. ($ROIV) stake by 12.4% last quarter, cutting to 4,867,723 shares worth $146.23 million.
- Wall Street's consensus rating on $ROIV is Strong Buy and an average price target of $39.04.
- $ROIV last traded around $30.04.
Baker Bros. Advisors reduced its position in Roivant Sciences Ltd. ($ROIV) by 12.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,867,723 shares of Roivant Sciences Ltd. after selling 687,294 shares during the quarter. Baker Bros. Advisors's holdings in Roivant Sciences Ltd. were worth $146.23 million as of its most recent filing.
Roivant Sciences Ltd. ($ROIV) Stock
Roivant Sciences Ltd. Earnings
Analysts Set New Price Targets
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.